In our previous study, we identified several PD-L1 variants (PD-L1–v242 and –v229) in samples from anti–PD-L1–treated lung cancer patients (LUSC and EGFR-mutated lung adenocarcinoma) (28). Here, EGFR is linked to lung cancer.